Cetilistat is an inhibitor of pancreatic lipase. It inhibited rat and human pancreatic lipase activity with an IC50 of 54.8 nmol/l, and 5.95 nmol/l, respectively. When cetilistat was orally administered simultaneously with fat emulsion to Sprague-Dawley rats, the elevation in plasma triglyceride concentration by oral fat loading was reduced by cetilistat in a dose-dependent manner at 3, 10, 30, and 100 mg/kg, indicating that cetilistat reduces intestinal fat absorption in rats. Furthermore, cetilistat was administered to DIO F344 rats as food admixture in a high-fat diet at 4.9, 14.9, or 50.7 mg/kg/day for three weeks. Both triglyceride and nonesterified fatty acid content in the feces were dose-dependently and drastically increased, suggesting the intestinal breakdown of fat and excretion. Body weight (BW) gain and white adipose tissue (WAT) weight were also reduced in a dose-dependent manner. Thus cetilistat ameliorates obesity and hyperlipidemia in DIO (diet-induced obesity rats) and useful for the study of human obesity.?

1.?Yamada Y, et al. Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. Horm Metab Res. 2008 Aug;40(8):539-43.